EP
RNAC icon

Essential Partners’s Cartesian Therapeutics RNAC Stock Holding History

Essential Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.44K Sell
339
-93
-22% -$810 ﹤0.01% 1846
2026
Q2 		$4.5K Sell
432
-165
-28% -$1.22K ﹤0.01% 1596
2026
Q1 		$3.67K Buy
+597
New +$4.25K ﹤0.01% 1725
2025
Q4 		– Sell
-14
Closed -$143 – 2895
2025
Q3 		$143 Sell
14
-1
-7% -$11 ﹤0.01% 2449
2025
Q2 		$156 Buy
+15
New +$160 ﹤0.01% 1999

Other funds holding RNAC

GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return

Essential Partners's RNAC Position: Q3 2026 in Review

Essential Partners reduced its Cartesian Therapeutics (RNAC) stake by 22% in Q3 2026, selling an estimated $810 and leaving 339 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1846.

Essential Partners first reported a position in RNAC in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.5K in Q2 2026. 6 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Essential Partners held 339 shares of Cartesian Therapeutics worth $2.44K as of Q3 2026.
  • Essential Partners sold 93 Cartesian Therapeutics shares in Q3 2026, an estimated $810.
  • Cartesian Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1846 holding.
  • Essential Partners first reported a position in Cartesian Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Cartesian Therapeutics position peaked at $4.5K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.